Sydney — March 5, 2026, 18:33 AEDT
- Pro Medicus ended Thursday’s session 4.6% higher at A$121.49.
- Despite the recent bounce, the stock is still off roughly 53% for the past year.
- Investors are balancing the company’s contract-fueled expansion with concerns over valuation and unpredictable accounting moves.
Pro Medicus finished the day up 4.6% at A$121.49, bumping its market cap to around A$12.1 billion. Despite Thursday’s climb, shares remain 53% lower year-on-year—still a long way from the 52-week peak of A$336, according to market data.
That jump is significant—Pro Medicus now stands as a sort of litmus test for how much risk investors are willing to take on pricey healthcare IT stocks after the recent pullback. Shares remain at a premium, so every rally comes with a sense of uncertainty.
Healthcare shares caught some of the action on Thursday, lifting the sector roughly 2.1%. Investors shifted toward defensive plays “trading on cheaper valuations,” according to IG, sending names like Telix Pharmaceuticals and CSL higher. IG
Pro Medicus makes software that hospitals use to store and view CT, MRI and other medical scans in a single platform. The company also offers a radiology information system, handling scheduling and billing behind the scenes for imaging departments.
For the half-year ended Dec. 31, the company posted a 28.4% lift in revenue from contracts with customers, reaching A$124.8 million. Net profit after tax came in at A$171.2 million, though that was heavily influenced by an unrealised fair value gain of A$149.1 million linked to its stake in 4D Medical—management highlighted that this number tracks 4D Medical’s share price. The board set a fully franked interim dividend at 32 cents per share, to be paid out March 20.
Back in February, CEO Sam Hupert dismissed concerns on the earnings call that generative AI could undercut the business, describing it as “a plus rather than a threat.” The company’s five-year contracted minimum revenue, he noted, had “broken through the AUD 1 billion mark.” Hupert highlighted a stream of new contract wins and recent implementations he expects will push second-half revenue higher. CFO Clayton Bain chimed in too, saying, “the second half will be bigger” as major rollouts start to accelerate. Investing.com
Pro Medicus, according to a separate ASX filing, is running an on-market buyback through March 31, 2026. Goldman Sachs is on as broker, and the program’s capped at roughly 10.45 million shares.
This week’s been a bumpy ride for the stock. On Tuesday, it finished at A$114.28, before recovering to A$116.19 the following day. Thursday saw another gain, price history data shows.
Enterprise imaging is turning into a tougher battleground. Hospitals are moving away from older picture-archiving systems, eyeing cloud-based platforms—upping the pressure on Pro Medicus as it faces off with established names like Philips, Sweden’s Sectra, and a mix of private companies. Radiology departments, meanwhile, are pushing hard for quicker tech that can keep up with bigger scans and heavier caseloads.
Still, the main uncertainties linger. Profits on paper are at the mercy of how the 4D Medical holding gets marked. If those major U.S. contracts take longer to launch, the company also faces a wait for the transaction fees that depend on exam numbers.
Investors want to see new contracts in the pipeline, some real evidence that big projects aren’t slipping off track, and a signal that the recent selloff has settled, not just taken a breather.
